Skip to main content

Advertisement

Table 3 Univariate and multivariate analyses for progression-free survival

From: Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients

  Univariate analysis  
Factors HR (95% CI) p value
Age (years)
 <50 (vs. ≥50) 1.23 (0.82–1.84) 0.322
Tumor origin
 Bone (vs. soft tissue) 1.05 (0.65–1.69) 0.843
Primary site   0.648
 Trunk (vs. extremities) 1.20 (0.67–2.15) 0.542
 Retroperitoneum (vs. extremities) 1.02 (0.56–1.85) 0.957
 Visceral (vs. extremities) 1.48 (0.78–2.83) 0.231
Histological subtype   0.008
 UPS (vs. leiomyosarcoma) 1.20 (0.61–2.35) 0.591
 Others (vs. leiomyosarcoma) 2.01 (1.23–3.21) 0.004
Prior chemotherapy   0.028
 Second-line (vs. first-line) 0.99 (0.55–1.78) 0.974
 Third-or-greater line (vs. first-line) 1.74 (0.97–3.12) 0.064
Response to GD
 SD/PD (vs. CR/PR) 2.05 (0.99–4.23) 0.053
  Multivariate analysis  
Factors HR (95% CI) p value
Age (years)
 ≥50 (vs. <50)   
Tumor origin
 Bone (vs. soft tissue)   
Primary site
 Trunk (vs. extremities)   
 Retroperitoneum (vs. extremities)   
 Visceral (vs. extremities)   
Histological subtype
 UPS (vs. leiomyosarcoma)   
 Others (vs. leiomyosarcoma)   
Prior chemotherapy   0.043
 Second-line (vs. first-line) 1.02 (0.56–1.83) 0.974
 Third-or-greater line (vs. first-line) 1.71 (0.95–3.07) 0.074
Response to GD
 SD/PD (vs. CR/PR)